Χώρα: Ιρλανδία
Γλώσσα: Αγγλικά
Πηγή: HPRA (Health Products Regulatory Authority)
Phenylbutazone
Dechra Ltd
QM01AA01
Phenylbutazone
200 milligram(s)/millilitre
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Horses, Non food-producing horses
phenylbutazone
N.S.A.I.D.
Authorised
2005-10-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Equipalazone 200 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Phenylbutazone 200 mg/ml Excipients Benzyl Alcohol 0.015 ml/ml For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses and ponies 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of musculo-skeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of phenylbutazone can offer relief against inflammation, pain and lameness (for example, osteoarthritis conditions, acute and chronic laminitis, bursitis and carpitis). 4.3 CONTRAINDICATIONS The therapeutic index of phenylbutazone is low. Do not exceed the stated dose or the duration of treatment. Do not administer with other non-steroidal anti-inflammatory agents concurrently or within 24 hours of each other. Do not use in animals suffering from cardiac, hepatic or renal disease; where there is the possibility of gastro-intestinal ulceration or bleeding; where there is evidence of a blood dyscrasia or of hypersensitivity to the product. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Discontinue treatment if no response is evident after four to five days treatment. The clinical effect of phenylbutazone can be evident for at least three days following cessation of administration. This should be borne in mind when examining horses for soundness. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Διαβάστε το πλήρες έγγραφο